GI
ELVN icon

GAMMA Investing’s Enliven Therapeutics ELVN Stock Holding History

GAMMA Investing’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.6K Buy
228
+6
+3% +$255 ﹤0.01% 3134
2026
Q1 		$8.7K Buy
222
+32
+17% +$887 ﹤0.01% 3143
2025
Q4 		$2.93K Sell
190
-12
-6% -$239 ﹤0.01% 3491
2025
Q3 		$4.13K Buy
202
+1
+0.5% +$20 ﹤0.01% 3246
2025
Q2 		$4.03K Buy
201
+63
+46% +$1.19K ﹤0.01% 3200
2025
Q1 		$2.72K Buy
138
+52
+60% +$1.12K ﹤0.01% 3316
2024
Q4 		$1.94K Buy
86
+20
+30% +$518 ﹤0.01% 3231
2024
Q3 		$1.69K Buy
66
+17
+35% +$394 ﹤0.01% 3117
2024
Q2 		$1.15K Sell
49
-4
-8% -$84 ﹤0.01% 3025
2024
Q1 		$932 Buy
53
+16
+43% +$245 ﹤0.01% 2958
2023
Q4 		$581 Buy
+37
New +$453 ﹤0.01% 2928

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

GAMMA Investing's ELVN Position: Q2 2026 in Review

GAMMA Investing increased its Enliven Therapeutics (ELVN) stake by 2.7% in Q2 2026, buying an estimated $255 and bringing the position to 228 shares worth $11.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3134.

GAMMA Investing first reported a position in ELVN in Q4 2023 and has held it in 11 quarters since. 210 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • GAMMA Investing held 228 shares of Enliven Therapeutics worth $11.6K as of Q2 2026.
  • GAMMA Investing bought 6 Enliven Therapeutics shares in Q2 2026, an estimated $255.
  • Enliven Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3134 holding.
  • GAMMA Investing first reported a position in Enliven Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 210 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.